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Abstract Antibiotic resistance continues to contribute signif-
icantly to morbidity and mortality across the world.
Developing new tests for antibiotic-resistant bacteria is a core
action to combat resistant infections. We describe a method
that uses phage amplification detection (PAD) combined with
matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-MS) to rapidly identify Staphylococcus aureus and
determine phenotypic susceptibility to cefoxitin. Samples test-
ed for S. aureus are incubated together with bacteriophage in
the presence and absence of cefoxitin and subjected to rapid
trypsin digestion followed by MALDI-MS analysis. Tryptic
peptides derived from amplified phage proteins can be detect-
ed by MALDI-MS, as validated by time-of-flight (TOF)/TOF
analysis of each peptide combined with database searching.
Methicillin-resistant S. aureus show significant phage ampli-
fication in the presence of cefoxitin, while methicillin-
sensitive S. aureus show no phage amplification relative to a
no-antibiotic control. We also show that PAD methodology
can be implemented on an FDA-approved commercial
MALDI-MS bacterial identification system to identify
S. aureus and determine antibiotic susceptibility. The novelty
of this assay includes the use of phage-derived tryptic peptides
as detected by MALDI-MS to monitor the results of PAD on
an instrument common to many modern microbiology
laboratories.
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Introduction
In 2013, the Centers for Disease Control and Prevention is-
sued a detailed report on the specter of antibiotic resistance
threats in the USA, describing the substantial burden of cur-
rent and emerging antibiotic-resistant strains of bacteria im-
posed on the US healthcare system [1]. Annually, in the USA,
at least two million people contract infections from antibiotic-
resistant bacteria, resulting in approximately 23,000 deaths.
Direct healthcare costs in the USA related to antibiotic-
resistant bacteria are as high as $20 billion, with estimates
for lost productivity ranging up to $35 billion [1]. While the
report focuses on antibiotic threats within the USA, it also
recognizes the worldwide nature of the antibiotic resistance
dilemma. The CDC outlines four core actions to combat
antibiotic-resistant infections, which includes Bdeveloping
new diagnostic tests for resistant bacteria^ [1].
Previous studies have demonstrated the feasibility of utiliz-
ing phage amplification detection (PAD) combined with mass
spectrometry to rapidly detect bacterial species from direct
culture [2–6] and determine its antibiotic susceptibility [7].
Bacteriophages are virus particles that can infect a bacterial
host, hijack the cell machinery of the host to produce clonal
progeny virus particles, and lyse the bacterial host, spilling the
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newly generated bacteriophages into the surrounding milieu.
PAD exploits the specificity of a bacteriophage for its host to
initiate a phage infection in the targeted bacterium, followed
by monitoring the sample for evidence of a successful bacte-
riophage infection, which implies the presence of the targeted
bacterium.Mass spectrometry functions as a PAD platform by
detecting the protein products of new phage replication, which
may include both structural and nonstructural protein markers.
Antibiotic resistance by PAD is determined by the detection of
phage replication in the presence of an antibiotic when com-
pared to a no-antibiotic control.
Matrix-assisted laser desorption/ionization mass spectrom-
etry (MALDI-MS) has been developed and introduced as a
commercial tool for the rapid detection of bacteria [8–10],
with efforts being made to expand its capabilities to include
antibiotic resistance determination [11–14]. MALDI-MS is an
attractive platform for bacterial detection because of the rela-
tive ease of sample preparation in combination with its ability
to analyze large numbers of samples in a short period of time.
While PAD combinedwith liquid chromatography-mass spec-
trometry (LC-MS) techniques can quantitatively identify bac-
teria and determine antibiotic susceptibility, the serial nature
of running samples on a liquid chromatography system—
however short the LC run—may limit the routine use of
PAD-LC-MS in a clinical setting. Furthermore, two MALDI
time-of-flight (TOF)-MS systems have been approved by the
FDA for routine identification of bacteria and are rapidly be-
ing deployed in clinical laboratories. Thus, clinically relevant
MALDI-MS assay development is of growing importance.
This study demonstrates PAD as a tool to determine the
presence of Staphylococcus aureus in a sample and determine
its antibiotic susceptibility using MALDI-MS as a detector.
Using 15N-labeled bacteriophage to initiate an infection, we
can ascertain the protein products of a successful phage am-
plification process using MALDI to detect three tryptic pep-
tides of the newly replicated bacteriophage. TOF/TOF analy-
sis of each peptide combined with database searching con-
firms that the targeted peptides at each mass are derived from
the capsid protein of newly generated bacteriophage. PAD of
S. aureus and antibiotic susceptibility determination by
MALDI-MS is shown to work on an FDA-approved platform
for bacterial identification.
Materials and methods
Bacterial strains and bacteriophage
All bacteria used in this study were purchased from the
American Type Culture Collection (ATCC) (Manassas, VA).
Antibiotic susceptibility for all strains of bacteria was deter-
mined according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines using the guiding document
M100-S25 as described elsewhere [7]. Details of each strain
used and antibiotic susceptibility determination results are
shown in Table 1. Bacteriophage K (ATCC-19685-B1) and
its host (ATCC-19685) were also purchased from the ATCC
and propagated, harvested, and quantified as described else-
where [7]. 15N-labeled bacteriophage K was generated by cul-
turing its host in 15N-labeled broth (Cambridge Isotope
Laboratories, Inc., Tewksbury, MA) and propagating the
phage in this host continually using the 15N-labeled broth.
Phage samples were stored at 4 °C until needed.
Phage amplification
Bacterial strains used in PAD experiments were grown over-
night in tryptic soy broth. Samples for identification were
generated by mixing each bacterium at a final concentration
of 2.5 × 107 cfu/mL with 15N-labeled bacteriophage at a final
concentration of 1 × 108 plaque-forming units (pfu)/mL and
incubating at 37 °C for 5 h. Samples for antibiotic suscepti-
bility were generated by mixing bacteria at a final concentra-
tion of 2.5 × 107 cfu/mL with cefoxitin at 4 μg/mL and incu-
bating at 37 °C for 2.5 h. Bacteriophage was added to each
cefoxitin-containing sample at a final concentration of 1 ×
108 pfu/mL and incubated an additional 2.5 h. Controls con-
taining only bacteriophage and only a bacterial strain were
incubated along with all samples for 5 h at 37 °C. Following
incubation, all samples were centrifuged briefly to remove
large debris, filtered through a 30-kDa molecular weight cut-
off filter (Amicon Ultra; Millipore, Billerica, MA), and
washed twice in the filter with 50mM ammonium bicarbonate
at pH 7.4.
Trypsin digestion
Tenmicroliters of each sample was mixed with 10 μL of 0.1%
RapiGest (Waters, Inc., Bedford, MA) and heated at 100 °C
for 10min. After the samples cooled, 10 μL of sequence grade
trypsin (Promega, Madison, WI) at 0.4 μg/mL was added to
each sample and incubated at 52 °C for 3 min for enzymatic
digestion. Each sample was processed and purified using a
Table 1 List of Staphylococcus aureus strains used in this study along
the antibiotic susceptibly testing results
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C18 ZipTip (Millipore, Billerica, MA) prior to MALDI
plating.
MALDI-MS analysis
Samples for MALDI-MS analysis using an Applied
Biosystems (Framingham, MA) model 4800 MALDI-TOF/
TOF instrument were spotted onto a 384-position MALDI
plate by mixing 0.5 μL of sample with 0.5 μL of alpha-
cyano-4-hydroxycinnamic acid at each spot. Mass spectra of
each spot were obtained by scanning 2000 to 3000m/z in MS-
positive ion reflector mode. Fragment ion spectra were obtain-
ed for designated masses using the instrument in TOF/TOF
mode. The instrument uses a ND:YAG laser at 355 nm, and
each spectrum is the average of 9800 laser shots. Samples for
analysis on the Bruker Biotyper were prepared by mixing
1.0 μL of the sample with 1.0 μL of alpha-cyano-4-
hydroxycinnamic acid at each spot. The instrument operates
in linear mode, and samples were scanned over the range
2000–3000 m/z.
Peaks from each TOF/TOF fragment ion spectrum were
extracted using a Mascot Distiller (Matrix Science, London,
UK; version 2.5.1) and searched against a database of bacte-
riophage K protein sequences culled from the NCBInr data-
base (www.ncbi.nih.gov) using the Mascot search algorithm
(Matrix Science, London, UK; version 2.5.1).
Results and discussion
The MALDI spectrum of a tryptic digest of isolated wild-type
bacteriophage K at 5 × 108 pfu/mL is shown in Fig. 1, with
peaks at m/z that correspond to peptides discovered by LC-
MS/MS and database searching highlighted (see Electronic
Supplementary Material (ESM) Table S1). Intense peaks at
m/z 2111.1, m/z 2399.3, and m/z 2609.4 correspond in mass
to the bacteriophage K capsid protein tryptic peptides
( K ) S F Q T G Y G I T P D T Q I D A G A L R ( R ) ,
( K ) L S I N VNAMYQQQ P Q F V S I Y R ( Q ) , a n d
(K)GFGTATDAYMPIGVHADFVNSILGR(Q), respectively.
TOF/TOF analysis of each respective peak is shown in Fig. 2,
and database searching of each fragment ion spectrum against
a bacteriophage K sequence database resulted in a singular,
significant database identification that matched the amino acid
sequences of the respective MS peaks. Further evidence that
these peaks are tryptic peptides belonging to bacteriophage K
is revealed upon comparison of wild-type bacteriophage K
with 15N-labeled bacteriophage shown in Fig. 3. The mass
difference between the peak at m/z 2111 and m/z 2136 corre-
sponds with the exact number of nitrogen atoms (25) in the
peptide (K)SFQTGYGITPDTQIDAGALR(R). TOF/TOF
analysis of the peak at m/z 2136 reveals a fragment ion spec-
trum identical to the spectrum derived from the peak at m/z
2111 after accounting for the number of nitrogen atoms in
each fragment. This similar observation can be made for the
pairs of peaks at m/z 2399 and m/z 2428 and at m/z 2609 and
m/z 2640.
The detection limit for bacteriophage K was determined by
a 50% serial dilution series beginning at 5 × 108 pfu/mL down
to 7.8 × 106 pfu/mL. Fig. S1 (see ESM) shows the MALDI
spectrum of relevant dilutions, revealing that S/N falls below
detection levels at approximately 1 × 108 pfu/mL. Thus, any
bacteriophage amplification event must produce at least 1 ×
108 pfu/mL of phage K in order to generate enough MALDI-
MS signal to be deemed a successful infection and the pres-
ence of S. aureus established.
A detection experiment was conducted such that four
strains of S. aureus (ATCC-12598, ATCC-27694, BAA-
Fig. 1 MALDI-MS spectrum of tryptic peptides derived from wild-type
bacteriophage K. The peak masses correspond to the following peptide
sequences: 2111.121 (SFQTGYGITPDTQIDAGALR), 2399.314
( L S I N V N A M Y Q Q Q P Q F V S I Y R ) , a n d 2 6 0 9 . 3 8 5
(GFGTATDAYMPIGVHADFVNSILGR)
Fig. 2 TOF/TOF spectra of three tryptic peptides derived from
bacteriophage K
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1720, and BAA-1750) at 2.5 × 107 cfu/mL were infected with
an inoculum of 15N bacteriophage at an initial concentration
of 1 × 108 pfu/mL. Tryptic peptide peaks associated with new-
ly propagated bacteriophage should contain predominantly
14N, because the broth used to culture the bacterial host con-
sists of nutrients with nitrogen isotopes at natural abundances.
Figure 4 displays the MALDI spectrum of each respective
amplification event, showing the appearance of the
established three tryptic bacteriophage peaks at m/z 2111, m/
z 2399, and m/z 2609. Mass spectra obtained from controls
consisting of only bacteriophage K (no bacteria) and bacteria
only (no labeled phage K) carried through the infection and
digest procedures revealed no amplified phage peaks and no
peaks that may interfere with peaks associated with newly
amplified bacteriophage (ESM Fig. S2). Thus, the presence
of S. aureus in the respective cultures can be established after a
5-h infection process based upon the detection of phage
amplification.
Antibiotic susceptibility of the four strains of S. aureus to
4 μg/mL cefoxitin was determined by carrying out a bacteri-
ophage amplification experiment in the presence of the anti-
biotic with comparison to a no-antibiotic phage amplification
infection as demonstrated above. Because bacteriophage can
replicate only in living bacteria, no phage amplification—and
therefore no phage proteins—is expected in antibiotic suscep-
tible S. aureus strains. Figure 5 shows the side-by-side com-
parison of each respective S. aureus strain after phage ampli-
fication with the no-antibiotic sample and in the presence of
4 μg/mL cefoxitin. For the two methicillin-sensitive S. aureus
(MSSA) strains—ATCC-12598 and ATCC 27694—signifi-
cant amplification can be seen in the no-antibiotic samples
as shown in Fig. 4, while no phage-based tryptic peaks can
be detected in the sample with cefoxitin; phage replication did
not occur to produce the 14N-labeled progeny phage, and the
15N parent phage is below the limit of detection of the
MALDI-TOF-MS. Therefore, not only can the presence of
S. aureus can be determined in these samples, but they are
also susceptible to cefoxitin. The methicillin-resistant
S. aureus (MRSA) strains BAA-1720 and BAA-1750 show
significant phage amplification in both the no-antibiotic and
the cefoxitin-containing samples, indicating that live S. aureus
bacteria in the cefoxitin-containing sample were responsible
for the phage amplification. Thus, the presence of S. aureus is
established in these two samples, and their susceptibility to
cefoxitin is confirmed.
While the above experimentation for PAD combined with
MALDI was conducted on a research grade instrument with
TOF/TOF capabilities in reflector mode, MALDI instrumen-
tation in clinical laboratories often consists of instruments that
function in linear ion modewithout a reflectron. Because of the
expanding use and distribution of these commercial instru-
ments, it would be useful to establish the use of PAD as de-
tected on contemporary instrumentation such as the Bruker
Biotyper or the BioMerieux VITEK MS that have been ap-
proved by the FDA for routine bacterial identification in clin-
ical laboratories. Figure 6 shows the MALDI-MS spectra ob-
tained on a Bruker Biotyper of the phage amplification tryptic
products of the four S. aureus strains used in this study incu-
bated in the no-antibiotic sample and in the presence of 4 μg/
mL cefoxitin. While the MSSA strains ATCC-12598 and
ATCC-27694 show clear phage amplification as determined
by the presence of the peaks at m/z 2111, m/z 2399, and m/z
2609 in the sample with no antibiotic, the spectra of the phage
amplification products in the presence of 4 μg/mL cefoxitin
show no peaks indicative of a successful phage amplification
event which require live bacteria. Thus, these strains would be
accurately identified as S. aureus and would be deemed sus-
ceptible to cefoxitin. TheMRSA strains BAA-1720 and BAA-
1750 show phage amplification in both the no-antibiotic and
4 μg/mL preparations, successfully identifying each strain as
S. aureus and determining its susceptibility to cefoxitin.
While detection of bacteria using PAD detected by
MALDI-MS has been shown previously, to our knowledge,
this is the first study showing the ability to ascertain antibiotic
susceptibility by PAD as detected by MALDI-MS. Moreover,
this is the first study using tryptic peptides of amplified phage
proteins to detect phage amplification by MALDI-MS. In our
experience, high-mass (>20 kDa), intact proteins derived from
bacteriophage cannot always be detected by MALDI-MS, re-
gardless of phage concentration. For example, while the cap-
sid protein for S. aureus bacteriophage 53 is readily detected
by MALDI-MS with basic sample preparation techniques [4],
we have been unable to detect the intact major phage capsid
protein for phage K by MALDI-TOF-MS regardless of sam-
ple preparation techniques, which include a reduction of
Fig. 3 Comparison of wild-type phageKwith 15N-labeled bacteriophage
K. The shift in masses between the wild-type and 15N-labeled
bacteriophage corresponds precisely to the number of nitrogen atoms in
the amino acid sequences of the peptides assigned to each respectivemass
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disulfide bonds and sonication. However, with all bacterio-
phages in our laboratory, we have been able to detect tryptic
peptides of phage proteins following trypsin digestion regard-
less of the bacteriophage in question.
We believe that demonstration of PAD on MALDI-MS
instrumentation to detect bacteria and determine antibiotic
susceptibility is a significant and novel step forward in inte-
grating PAD for everyday clinical use. The use of trypsin
digestion prior to MALDI-MS analysis means that many
hard-to-detect (by MALDI-MS) bacteriophages using whole,
intact virus analysis can likely be used in a PAD schemewhere
MALDI-MS is used as a detector. In our experience, we have
been able to detect proteins from all bacteriophages at signif-
icant quantities using trypsin digestion prior to MS analysis,
whereas MALDI-MS of whole, intact viruses often fails to
detect any virus-derived proteins. We anticipate the continued
acceptance of commercial MALDI-MS instrumentation for
bacterial diagnostics and believe that PAD reagents and
methodologies can be integrated into instruments already in
place in microbiology and clinical laboratories. While
MALDI-MS instrumentation is already capable of identifying
bacteria from pure culture, PAD by MALDI-MS adds the
component of antibiotic susceptibility determination to the
MALDI-MS platform. As we have already demonstrated,
PAD can be utilized to detect susceptibility to multiple antibi-
otics [7]. PAD in clinical samples can be conducted in
multiple-well formats, lending itself to the processing of mul-
tiple samples in parallel and subsequent spotting on MALDI
plates prior to analysis. Because MALDI-MS functions as a
universal detector, obviating the need to develop and validate
antibody-based detection systems, PAD kits can be added di-
rectly to existingMALDI-MS-based detection systems as they
are developed and validated.
Several advantages combining PAD with MALDI-MS to
identify bacteria and determine antibiotic resistance are appar-
ent. First, while MALDI-MS currently relies upon the
Fig. 4 MALDI spectra of four
strains of S. aureus after a 5-h
PAD experiment. Phage
amplification is detected in all
strains of S. aureus
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isolation of bacterial colonies prior to analysis, PAD can iden-
tify bacteria in mixtures [5], thereby significantly shortening
the time to detection (5 h) because extended incubation times
to visualize and obtain colonies can be avoided. Second, mul-
tiple antibiotics can be added to PAD workflows to obtain
antibiotic susceptibility information against a panel of antibi-
otics. As phage replication is dependent upon a viable bacte-
rial host, any agent that arrests growth or kills bacteria can be
tested using PAD. Third, if a phage cocktail is utilized that
contains typing phages, MALDI-MS can identify by mass
which respective phage is amplified, thereby providing addi-
tional epidemiological data.
The single major barrier to implementation of a phage-
based assay, in our opinion, is obtaining a bacteriophage or
formulating a phage cocktail that has the requisite sensitivity
and specificity. Phage detection systems do exist that incorpo-
rate a single bacteriophage; for example, the gamma phage
lysis test to detect Bacillus anthracis is widely used in cases
of anthrax outbreaks [15]. Contrariwise, the KeyPath MRSA/
MSSA blood culture test incorporates a phage cocktail to ob-
tain suitable sensitivity and specificity [16, 17]. Phage K, uti-
lized in the present study, has a broad host range for many
strains of S. aureus yet has been shown to also infect a small
number of Staphylococcus epidermidis strains [18]. Thus, if
phage K was to be incorporated into an assay, it would have to
be augmented with other S. aureus bacteriophages, and the
cross-reactivity to S. epidermidis would have to be mitigated,
for example by the addition of the iron chelator deferoxamine
to inhibit the growth of S. epidermidis strains [19].
While this study lays the methodological foundation for a
PAD assay using MALDI-TOF-MS to identify S. aureus and
determine antibiotic susceptibility, a robust validation must
occur before moving to clinical implementation. Many more
strains of bacteria including MSSA, MRSA, and common
Fig. 5 MALDI spectra of four
strains of S. aureus after a 5-h
PAD amplification experiment in
the presence of 4 μg/mL
cefoxitin. Phage amplification can
be seen in methicillin-resistant
bacteria BAA-1720 and BAA-
1750, while no amplification is
noted in the methicillin-sensitive
S. aureus strains
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contaminating bacteria such as S. epidermidis must be tested
to ensure broad-enough coverage while minimizing false pos-
itives. Importantly, S. aureus strains with MICs near the CLSI
cefoxitin susceptibility (<4 μg/mL) and resistance (<8 μg/mL)
values should be represented. Because of the ease of modify-
ing this method, moving to a cutoff of 8 μg/mL cefoxitin may
be warranted as more S. aureus strains are tested to ensure
strains of intermediate resistance are properly assigned accu-
rate susceptibility status. For the purposes of a PAD assay, the
proper concentration of cefoxitin used must be determined
empirically. For example, the FDA-approved KeyPath phage
amplification detection methodology used 2 μg/mL cefoxitin
as the cutoff point in its assay [16, 17].
Conclusion
PAD followed by trypsin digestion and MALDI-MS analysis
can identify S. aureus in samples and determine antibiotic
susceptibility. PAD methodologies can be implemented on
MALDI-MS instrumentation already available in many
healthcare settings. The next step in incorporating PAD with
Fig. 6 MALDI-MS spectra of PAD with four strains of S. aureus with and without antibiotic (4 μg/mL cefoxitin) obtained on a Bruker Biotyper
instrument
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MALDI-MS is the development of a phage or phage cocktail
that has a broad-enough host range to generate the necessary
sensitivity and specificity to provide actionable information.
MALDI-MS is an ideal platform for PAD as it functions as a
universal detector, expediting the research and development
of new phage/host systems as it makes antibody-based detec-
tion platforms unnecessary. Further, phage/host systems for
numerous bacteria can be deployed on MALDI-MS systems
already in place in microbiology laboratories.
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